Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal

... opioid use can lead to dependence and withdrawal. avigen scientists, led by Kirk Johnson, Ph.D., Vice Presi...Watkins is co-author of the paper, and a long-time avigen collaborator. "The potential for this agent is far...ids, anticonvulsants, and antidepressants. About avigen ...

Avigen in Biological Technology

Leading Advisory Firm, PROXY Governance, Recommends Avigen Shareholders Vote on GOLD Card to Remove Incumbent Directors and Elect BVF's Stockholder-Oriented Nominees

NEW YORK, March 23 /PRNewswire/ -- Biotechnology Value Fund, L.P. ("BVF") today announced that PROXY Governance, widely recognized as a leading independent proxy advisory firm, has recommended that shareholders vote for all BVF Proposals on the GOLD proxy card for the special meeting of Avigen, In...

BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009

NEW YORK, March 6 /PRNewswire/ -- BVF Acquisition LLC (the "Purchaser"), an affiliate of Biotechnology Value Fund L.P. ("BVF"), which has commenced a cash tender offer to purchase all of the outstanding shares of Avigen, Inc. (Nasdaq: AVGN ) ("Avigen") for $1.00 per share, announced today that i...

BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009

NEW YORK, Feb. 20 /PRNewswire/ -- BVF Acquisition LLC (the "Purchaser"), an affiliate of Biotechnology Value Fund L.P. ("BVF"), which has commenced a cash tender offer to purchase all of the outstanding shares of Avigen, Inc. (Nasdaq: AVGN ) ("Avigen") for $1.00 per share, announced today that i...

Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders

Raises Questions to be Addressed by Board and Management on Avigen's February 11, 2009 Conference Call SAN FRANCISCO, Feb. 10 /PRNewswire/ -- Biotechnology Value Fund, L.P. ("BVF"), today called for the management of Avigen, Inc. (Nasdaq: AVGN ) to address certain fundamental questions BV...

BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share

NEW YORK, Jan. 23 /PRNewswire/ -- BVF Acquisition LLC (the "Purchaser"), a wholly owned subsidiary of Biotechnology Value Fund, L.P. ("BVF"), announced today that it has commenced a cash tender offer to purchase any and all of the outstanding common stock of Avigen, Inc. (Nasdaq: AVGN ) ("Avigen...

Biotechnology Value Fund, L.P. To Make Tender Offer For Any And All Outstanding Shares Of Avigen At $1.00 Per Share

Tender Offer provides stockholders with a near-term cash alternative if BVF nominees are elected BVF reaffirms support for downside-protected merger with MediciNova NEW YORK, Jan. 15 /PRNewswire/ -- Biotechnology Value Fund, L.P. ("BVF") announced today that it intends to make a cash te...

Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees

Calls Special Meeting to Enable Stockholders to Determine Fate of Company's Remaining Cash Believes Transaction Proposed by MediciNova, Inc. Offers Avigen Stockholders Extraordinary Risk/Reward Opportunity SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Biotechnology Value Fund, L.P. together with...

Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders

...L.P. ("BVF"), today announced that stockholders of avigen (Nasdaq: AVGN ) voted overwhelmingly to remove the existing Board of Directors of avigen and replace them with BVF's nominees. The vote took place earlier today at the special meeting of avigen stockholders called by BVF. The preliminary vote c...

Empirical Search Strategies Seeks Downside Protection Option at Avigen, Inc.

...dity option, shareholders who decide to exit their avigen position for individual reasons (or those who view.... It is not uncommon to see a 5% bid/ask spread in avigen stock on any given day. ...in the future. Third, avigen is not a bank. Management should focus on selling ...

Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value

... stockholders to remove the current members of the avigen Board and replace them with BVF's four new, stockh...HO ARE DEDICATED TO MAXIMIZING VALUE FOR ALL avigen STOCKHOLDERS BY REDUCING CORPORATE WASTE AND PRO...e lead in protecting value for all stockholders of avigen in October of 2008, the stock price has increased ...